-
Your selected country is
Belgium
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Cytognos™ Primary Immunodeficiency Orientation Tube
(IVD)
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Description
The Primary Immunodeficiency Orientation Tube (PIDOT) is comprised of a pre-mixed 6-color 10-antibody combination and two single antibody vials: CD27-BV421 and CD45RA-BV510. The panel is designed for the screening of suspected primary immunodeficiencies by flow cytometry using BD FACSCanto™ II and/or BD FACSLyric™. It is intended to be used for staining of peripheral blood specimens. It can be used to study the changes in the relative distribution of the different leukocyte populations and sub-populations.
The Primary Immunodeficiency Orientation Tube recognizes the following antigens: CD45RA, CD27, CD8, IgD, CD16, CD56, CD4, IgM, CD19, TCR-?d, CD3 and CD45.
Description | Quantity/Size | Part Number | EntrezGene ID |
---|---|---|---|
Primary Immunodeficiency Orientation Tube | 5 Tests (4 ea) | CYT-PIDOT8-V | N/A |
CD4+IgM-PerCP-Cyanine5.5 Compensation | 1 Test (1 ea) | CYT-PIDOT8-CD4COMP | N/A |
CD19+TCRgd-PE-Cyanine7 Compensation | 1 Test (1 ea) | CYT-PIDOT8-19TCRCOMP | N/A |
CD45-APC-C750 Compensation | 1 Test (1 ea) | CYT-PIDOT8-CD45COMP | 5788 |
CD27-BV421 | 50 Tests (1 ea) | CYT-PIDOT8-27BV421 | 939 |
CD45RA-BV510 | 50 Tests (1 ea) | CYT-PIDOT8-45RABV510 | 5788 |
Bulklysis | 20 Tests (1 ea) | CYT-PIDOT8-BL | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostics Use.
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.